The subject of gene therapy first came up in the late 1960s and early 1970s, and is still the latest innovation in the field of medicine. Gene therapy works on the basis of manipulating the basis of human inheritance, the DNA. In a lot of medical conditions, the underlying problem is an abnormality in the gene which is the basic building block of inheritance and transfer of information from generation to generation. Gene therapy can be broadly defined as a branch of biomedical engineering which deals with the insertion, withdrawal or alteration of DNA (gene) within specific cells in order to treat a medical condition. Usually, the most common form of gene therapy involves the insertion of an artificially synthesized gene into a specific genetic locus to replace a transformed gene.
At a glance
- Discusses HSV-tk gene therapy and radiotherapy in an RM-1 mouse model
- Examines combined HSV-tk suicide gene therapy and radiotherapy
- 15 sources in the bibliography
Contents
1. Gene therapy and prostate cancer
Objective and Topics
This work examines the principles of gene therapy and their application to prostate cancer, considering how genetic interventions and combinations with radiotherapy may be used in treatment. Its guiding question is how these approaches work and what possibilities, risks and challenges they present.
- Definitions and history of gene therapy
- Germline and somatic gene therapy
- Viral and non-viral gene delivery vectors
- Prostate cancer and the p53 and p16 genes
- Potential risks and ethical considerations
- Combination of gene therapy and radiotherapy
Excerpt from the Book
Gene therapy and prostate cancer
The subject of gene therapy first came up in the late 1960s and early 1970s, and is still the latest innovation in the field of medicine. Gene therapy works on the basis of manipulating the basis of human inheritance, the DNA (Saraswat et al. 2009). In a lot of medical conditions, the underlying problem is an abnormality in the gene which is the basic building block of inheritance and transfer of information from generation to generation. Gene therapy can be broadly defined as a branch of biomedical engineering which deals with the insertion, withdrawal or alteration of DNA (gene) within specific cells in order to treat a medical condition (Mammen et al. 2007). Usually, the most common form of gene therapy involves the insertion of an artificially synthesized gene into a specific genetic locus to replace a transformed gene.
The first gene therapy was conducted on a four-year old girl, Ashanti DeSilva, on the fourteenth of September, 1990. The procedure was conducted by researchers at the United States National Institutes of Health on the patient who had a disorder of the immune system, specifically Severe Combined Immune Deficiency (SCID). The procedure was successful as the girl was able to recover but the effects showed only for a short period of time. Since then, there have been several modifications to the concept. Newer versions of the procedure attempt to directly repair errors in the products of the damaged or altered genes. Repairs are made on the messenger RNA which is produced from the altered gene (Baoutina et al. 2007).
The death of a patient, Jesse Gelsinger, undergoing gene therapy trial for ornithine transcarboxylase deficiency (OTCD) in 1999 brought about a minor setback in the development of gene therapy. This occurrence resulted in the Food and Drug Administration suspending all clinical trials on gene therapy as the ethical implications of the whole procedure were reassessed again. However, after some time, the ban was lifted and subsequent trials were much more successful. Since 2001, there have been significant achievements in the history of development of gene therapy. Several patients have been successfully cured of conditions such as metastatic melanoma and diseases affecting the myeloid cells.
Chapter Summary
Gene therapy and prostate cancer: The work introduces gene therapy, its history and delivery methods before discussing genetic targets and treatment strategies for prostate cancer. It also considers potential risks and the combination of gene therapy with radiotherapy.
Keywords
gene therapy, prostate cancer, DNA, germline therapy, somatic gene therapy, viral vectors, non-viral vectors, p53, p16, tumour suppressor genes, radiotherapy, suicide gene therapy, treatment risks
Frequently Asked Questions
What is this work about?
It explores gene therapy and its application to the treatment of prostate cancer.
What are its central topics?
The work addresses types of gene therapy, delivery vectors, genetic targets, treatment risks and combinations with radiotherapy.
What is the primary objective?
The objective is to explain how gene therapy may be applied to prostate cancer and to consider the possibilities and challenges of this approach.
What scientific method does the work use?
It presents a discussion based on published literature and cited clinical and preclinical studies.
What does the main discussion cover?
It covers gene delivery, tumour suppressor genes, potential adverse effects and approaches that combine gene therapy with radiation.
Which keywords characterize the work?
Key terms include prostate cancer, gene therapy, vectors, p53, p16 and radiotherapy.
How are p53 and p16 related to the discussion?
They are presented as genes relevant to prostate cancer and as potential targets for gene-based treatment strategies.
What combination treatment is discussed?
The work discusses combining HSV-tk suicide gene therapy with radiotherapy, including an example involving the RM-1 prostate cancer cell line in mice.
- Quote paper
- Dr P. Ronald (Author), 2011, Gene Therapy and Prostate Cancer, Munich, GRIN Verlag, https://www.grin.com/document/368311